Approval · Notice of Compliance 20752 · 2018
ILEVRO: Notice of Compliance 20752
Issued April 13, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20752
- Date
- April 13, 2018
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To provide for the addition of an alternate drug product manufacturing, packaging, labelling and testing site and for the addition of a new primary container
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ILEVRO | Not yet assigned | — |
Medicinal ingredients
- NEPAFENAC 3 MG per ML